

IL13R α 2 CAR T Cell Study

For: SOLID TUMOR CANCERS

Phase 1 Study of Systemically Administered IL13R α 2 Chimeric Antigen Receptor (CAR) T cells after a Chemotherapy Regimen

ENROLLING NOW at UCLA

POPULATION

- Stage IIIC or IV melanoma (including brain metastases)
- Other metastatic, non-CNS solid tumors after Standard of Care therapy
- Confirmed IL13R α 2 tumor expression
- Adequate Bone Marrow and Major Organ Function to Undergo a Stem Cell Transplant
- Willing/able to sign Informed Consent

INVESTIGATIONAL THERAPY

- Lymphodepleting Chemotherapy: Cyclophosphamide + Fludarabine
- IL13R α 2 directed Chimeric Antigen Receptor (CAR) T cells

- ❖ IL13R α 2 CART cells is an investigational therapy for patients with advanced solid tumors whose cancer expresses the IL13R α 2 protein.
- ❖ The cells are collected from the patient, gene-modified and then re-infused after chemotherapy.

FOR MORE INFORMATION:

<https://classic.clinicaltrials.gov/ct2/show/NCT04119024>

CONTACTS:

Principal Investigator: *Dr. Antoni Ribas, MD, PhD*; UCLA

Coordinator: *Christy Sidhu*; UCLA

Email: PICICenterResearch@mednet.ucla.edu

Phone: (310) 206-5087